Ascelia Pharma AB (publ) (ACE) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ascelia Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT NOTE Transcription provided by Deepgram Request Id: 01a0425b-2bd0-7c12-9a64-8c1f901851ed Created: 2026-08-27T08:34:27.812Z Duration: 1337.3387 Channels: 1 00:00:00.000 -- 00:00:02.480 Welcome everyone to the webcast for Ascelia Pharma's 00:00:02.480 -- 00:00:04.960 Q1 report for 2026. 00:00:07.200 -- 00:00:08.960 On this call we will be making forward 00:00:08.960 -- 00:00:10.240 looking statements. 00:00:11.280 -- 00:00:13.120 On today's call we will start with an 00:00:13.120 -- 00:00:15.599 overview of Ascelia Pharma and recent key events, 00:00:15.585 -- 00:00:17.665 and then we'll head into the portfolio update 00:00:17.665 -- 00:00:20.224 before moving to financials and priorities ahead. 00:00:20.785 -- 00:00:22.945 After the presentation, we will open up for 00:00:22.945 -- 00:00:23.585 questions. 00:00:25.585 -- 00:00:27.744 At Ascelia Pharma, we identify, 00:00:27.744 -- 00:00:30.610 develop and commercialize novel drugs that address unmet 00:00:30.610 -- 00:00:33.010 medical needs within rare cancer conditions. 00:00:33.650 -- 00:00:36.130 Our company is based in Malmo, Sweden and 00:00:36.130 -- 00:00:38.690 we are listed on NASDAQ's Defy, develop and 00:00:38.690 -- 00:00:41.490 commercialize novel drugs that address unmet medical needs 00:00:41.490 -- 00:00:42.850 within rare cancer conditions. 00:00:43.725 -- 00:00:46.285 Our company is based in Malmo, Sweden and 00:00:46.285 -- 00:00:48.205 we are listed on Nasdaq Stockholm. 00:00:49.325 -- 00:00:51.565 We have two drugs in our pipeline. 00:00:52.125 -- 00:00:54.525 OrbiGlambs is a diagnostic drug that is now 00:00:54.525 -- 00:00:57.005 under FDA review with a PDUFA date of 00:00:57.005 -- 00:00:59.250 07/03/2026. 00:00:59.809 -- 00:01:01.489 We will spend the majority of this call 00:01:01.489...